OriGene Technologies, Inc.
http://www.origene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OriGene Technologies, Inc.
Deals Shaping The Medical Industry, October 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
Medical Device Deals Update, October 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-September 2015.
Investors Focus On Devices, Services In China, But Drug R&D Still Has Some Attraction
China attracted $1.9 billion in private equity investment in health care-related fields in 2013, making the sector second only to real estate. But investors at a recent forum in Beijing had divergent opinions on whether the smart money should head into developing devices, clinics or new drug R&D.
Deals In Depth: April 2013
Roche is optioning Isis’ Huntington’s disease antisense candidates in a deal worth $282 million and Thermo Fisher paid just over $15 billion for Life Technologies. Biopharma financing was up 23% to $1.2 billion, device fundraising down 35% to $338 million.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics